Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03DX Other systemic drugs for obstructive airway diseases
R03DX09 Mepolizumab
D04923 Mepolizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Respiratory Tract Agents, Other
Immunomodulators
Mepolizumab
D04923 Mepolizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
22 Respiratory organ agents
229 Miscellaneous
2290 Miscellaneous
D04923 Mepolizumab (USAN/INN); Mepolizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Immunological agent
DG02019 Interleukin inhibitor
D04923 Mepolizumab
Drug classes [BR:br08332]
Immunological agent
DG02019 Interleukin inhibitor
D04923 Mepolizumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Interleukins
IL5
D04923 Mepolizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04923
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04923
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04923
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04923
